|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NYAP2 |
Gene summary for NYAP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NYAP2 | Gene ID | 57624 |
| Gene name | neuronal tyrosine-phosphorylated phosphoinositide-3-kinase adaptor 2 | |
| Gene Alias | KIAA1486 | |
| Cytomap | 2q36.3 | |
| Gene Type | protein-coding | GO ID | GO:0000902 | UniProtAcc | Q9P242 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57624 | NYAP2 | HCC1 | Human | Liver | HCC | 3.64e-19 | 1.25e+00 | 0.5336 |
| 57624 | NYAP2 | HCC2 | Human | Liver | HCC | 2.54e-34 | 1.88e+00 | 0.5341 |
| 57624 | NYAP2 | HCC5 | Human | Liver | HCC | 1.35e-37 | 1.66e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NYAP2 | SNV | Missense_Mutation | c.180G>T | p.Glu60Asp | p.E60D | Q9P242 | protein_coding | deleterious(0.04) | probably_damaging(0.99) | TCGA-AH-6544-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| NYAP2 | SNV | Missense_Mutation | c.266N>A | p.Gly89Asp | p.G89D | Q9P242 | protein_coding | deleterious(0.02) | benign(0.273) | TCGA-CI-6624-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NYAP2 | SNV | Missense_Mutation | c.1703N>T | p.Ala568Val | p.A568V | Q9P242 | protein_coding | tolerated(0.23) | benign(0.001) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NYAP2 | SNV | Missense_Mutation | novel | c.709N>A | p.Asp237Asn | p.D237N | Q9P242 | protein_coding | tolerated(0.06) | probably_damaging(0.997) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NYAP2 | SNV | Missense_Mutation | rs753863721 | c.1926N>T | p.Gln642His | p.Q642H | Q9P242 | protein_coding | tolerated_low_confidence(0.07) | possibly_damaging(0.66) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| NYAP2 | deletion | Frame_Shift_Del | c.939delN | p.Lys316ArgfsTer57 | p.K316Rfs*57 | Q9P242 | protein_coding | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
| NYAP2 | insertion | Frame_Shift_Ins | novel | c.1017_1018insC | p.Ala342ArgfsTer90 | p.A342Rfs*90 | Q9P242 | protein_coding | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NYAP2 | insertion | Frame_Shift_Ins | novel | c.212_213insG | p.Ile72AsnfsTer59 | p.I72Nfs*59 | Q9P242 | protein_coding | TCGA-AA-A01D-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD | ||
| NYAP2 | insertion | Frame_Shift_Ins | rs758750309 | c.945dupC | p.Lys316GlnfsTer116 | p.K316Qfs*116 | Q9P242 | protein_coding | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
| NYAP2 | SNV | Missense_Mutation | novel | c.26N>G | p.Ser9Cys | p.S9C | Q9P242 | protein_coding | deleterious(0) | possibly_damaging(0.575) | TCGA-4E-A92E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |